Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt
Open access

Regional astrocyte dysregulation and altered glymphatic‐related markers in Alzheimer's disease frontal cortex

Harry Alexopoulos X. Louka E. D. de Natale Kelly Koutroubi Lisa Cashmore M. Panayotacopoulou I. Trougakos H. Wilson M. Politis
Aug 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 40 references
Medicine

Abstract

Astrocyte dysfunction is central to Alzheimer's disease (AD), yet expression patterns of astrocytic markers remain poorly defined. We measured Aquaporin‐4 (AQP4) and glial fibrillary acidic protein (GFAP) in post‐mortem frontal cortex of AD patients and controls across BrainNet Europe (BNE) stages.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Aug 2026

When lactate speaks: Rewiring astrocyte-neuron metabolism in Alzheimer's disease.

Metabolic dysfunction is a defining but poorly understood feature of Alzheimer's disease. Du et al. show that a brain-penetrant GLP-1 receptor agonist rewires astrocyte-neuron metabolic coupling through lactate-driven histone lactylation, linking astrocytic glycolysis to neuronal lipid homeostasis and positioning metabolite signaling as a therapeutic axis in neurodegeneration.

Jessica Furtado, M. Schneeberger · 0 citations
Open access Aug 2026

Heterogeneity of GFAP Expression in Alzheimer’s Disease: A Perspective from the Vascular-Inflammation Axis

Based on the “vascular-inflammation axis” analytical framework, this study evaluates the pathophysiological significance of plasma glial fibrillary acidic protein (GFAP) in Alzheimer’s disease (AD). We systematically analyze its expression heterogeneity and clinical interpretive boundaries, specifically comparing late-onset AD (LOAD) and early-onset AD (EOAD).

Yi-Chen Chao, Yong-Chang Diwu · 0 citations
Open access Aug 2026

Plasma p‐tau217 detects Alzheimer's disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort

Cerebral amyloid angiopathy (CAA) frequently co‐occurs with Alzheimer's disease (AD), generating mixed vascular–neurodegenerative phenotypes. Plasma phosphorylated tau (p‐tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear.

A. Fernández-Lebrero, J. Jiménez-Balado, G. García‐Escobar et al. · 0 citations
Open access Aug 2026

Beyond amyloid: Contributions of neuroinflammation, cerebrovascular disease, and neurodegeneration to memory impairment in the oldest‐old, the LifeAfter90 Study

Neuroinflammatory processes may play a central role in promoting mixed pathologies and cognitive impairment in the oldest‐old. We hypothesize that elevated neuroinflammation, indicated by reactive astrocytosis, acts on cerebrovascular disease and separately, on amyloid beta (Aβ) pathology, to promote downstream medial temporal lobe atrophy and memory impairment.

Batool M. Rizvi, P. Maillard, A. Posis et al. · 0 citations
Open access Aug 2026

Brain morphometry patterns in the presence of Alzheimer's disease and/or LATE neuropathologic changes

Alzheimer's disease neuropathologic change (ADNC) and limbic‐predominant age‐related transactive response DNA‐binding protein 43 kDa (TDP‐43) encephalopathy neuropathologic change (LATENC) are common in older adults, yet differences in brain morphometry patterns when one or both pathologies are present remain unclear.

Khalid Saifullah, A. Ridwan, Arnold M. Evia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.